GT201200164A - "nuevos compuestos de espiropiperidina" - Google Patents
"nuevos compuestos de espiropiperidina"Info
- Publication number
- GT201200164A GT201200164A GT201200164A GT201200164A GT201200164A GT 201200164 A GT201200164 A GT 201200164A GT 201200164 A GT201200164 A GT 201200164A GT 201200164 A GT201200164 A GT 201200164A GT 201200164 A GT201200164 A GT 201200164A
- Authority
- GT
- Guatemala
- Prior art keywords
- spyropiperidine
- compounds
- new
- composite
- salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000002131 composite material Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26518109P | 2009-11-30 | 2009-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201200164A true GT201200164A (es) | 2014-02-27 |
Family
ID=43384775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201200164A GT201200164A (es) | 2009-11-30 | 2012-05-28 | "nuevos compuestos de espiropiperidina" |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8822486B2 (enExample) |
| EP (1) | EP2507228B1 (enExample) |
| JP (1) | JP5709889B2 (enExample) |
| KR (1) | KR101410103B1 (enExample) |
| CN (1) | CN102648195B (enExample) |
| AR (1) | AR078948A1 (enExample) |
| AU (1) | AU2010324987B2 (enExample) |
| BR (1) | BR112012012903A2 (enExample) |
| CA (1) | CA2781292C (enExample) |
| CL (1) | CL2012001321A1 (enExample) |
| CR (1) | CR20120296A (enExample) |
| DO (1) | DOP2012000139A (enExample) |
| EA (1) | EA020507B1 (enExample) |
| EC (1) | ECSP12011930A (enExample) |
| ES (1) | ES2526568T3 (enExample) |
| GT (1) | GT201200164A (enExample) |
| IL (1) | IL219594A0 (enExample) |
| MA (1) | MA33840B1 (enExample) |
| MX (1) | MX2012006233A (enExample) |
| NZ (1) | NZ600203A (enExample) |
| PE (1) | PE20121474A1 (enExample) |
| PH (1) | PH12012501052A1 (enExample) |
| TN (1) | TN2012000248A1 (enExample) |
| TW (1) | TW201141866A (enExample) |
| WO (1) | WO2011066183A1 (enExample) |
| ZA (1) | ZA201203055B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| PH12012501456A1 (en) | 2009-12-25 | 2012-10-29 | Mochida Pharm Co Ltd | Novel 3-hydroxy -5- arylisothiazole derivative |
| AU2011313191A1 (en) | 2010-10-08 | 2013-05-02 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| AR085990A1 (es) | 2011-04-27 | 2013-11-13 | Mochida Pharm Co Ltd | Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen |
| JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
| AR087451A1 (es) | 2011-08-17 | 2014-03-26 | Lilly Co Eli | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes |
| WO2014159054A1 (en) * | 2013-03-14 | 2014-10-02 | Janssen Pharmaceutica Nv | Gpr120 agonists for the treatment of type ii diabetes |
| CN105722841A (zh) | 2013-11-14 | 2016-06-29 | 卡迪拉保健有限公司 | 新型杂环化合物 |
| WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN110590767B (zh) * | 2019-08-29 | 2021-10-08 | 南方科技大学 | 一种合成amg837的方法 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| CA2520114A1 (en) | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists |
| US7504506B2 (en) | 2003-11-04 | 2009-03-17 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| EP1737809B1 (en) | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| CA2579204A1 (en) * | 2004-09-07 | 2006-03-16 | Banyu Pharmaceutical Co., Ltd. | Carbamoyl-substituted spiro derivative |
| MX2009000475A (es) * | 2006-07-19 | 2009-07-10 | Astrazeneca Ab | Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas. |
| EP2072519A4 (en) * | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | DIARYLKETIMINDERIVAT |
| PT2125827E (pt) * | 2006-12-29 | 2010-11-22 | Hoffmann La Roche | Derivados azaespiro |
| ES2446419T3 (es) * | 2007-04-16 | 2014-03-07 | Amgen, Inc | Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos |
| TWI421070B (zh) * | 2007-10-26 | 2014-01-01 | Japan Tobacco Inc | 螺化合物及其醫藥用途 |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
-
2010
- 2010-11-08 AR ARP100104151A patent/AR078948A1/es not_active Application Discontinuation
- 2010-11-10 TW TW099138725A patent/TW201141866A/zh unknown
- 2010-11-19 NZ NZ600203A patent/NZ600203A/xx not_active IP Right Cessation
- 2010-11-19 MX MX2012006233A patent/MX2012006233A/es not_active Application Discontinuation
- 2010-11-19 CA CA2781292A patent/CA2781292C/en not_active Expired - Fee Related
- 2010-11-19 BR BR112012012903A patent/BR112012012903A2/pt not_active IP Right Cessation
- 2010-11-19 CN CN201080054116.3A patent/CN102648195B/zh not_active Expired - Fee Related
- 2010-11-19 ES ES10784390.6T patent/ES2526568T3/es active Active
- 2010-11-19 AU AU2010324987A patent/AU2010324987B2/en not_active Ceased
- 2010-11-19 EP EP10784390.6A patent/EP2507228B1/en active Active
- 2010-11-19 PH PH1/2012/501052A patent/PH12012501052A1/en unknown
- 2010-11-19 JP JP2012542076A patent/JP5709889B2/ja not_active Expired - Fee Related
- 2010-11-19 US US13/505,470 patent/US8822486B2/en not_active Expired - Fee Related
- 2010-11-19 EA EA201290416A patent/EA020507B1/ru not_active IP Right Cessation
- 2010-11-19 PE PE2012000730A patent/PE20121474A1/es not_active Application Discontinuation
- 2010-11-19 KR KR1020127013788A patent/KR101410103B1/ko not_active Expired - Fee Related
- 2010-11-19 WO PCT/US2010/057359 patent/WO2011066183A1/en not_active Ceased
-
2012
- 2012-04-25 ZA ZA2012/03055A patent/ZA201203055B/en unknown
- 2012-05-03 IL IL219594A patent/IL219594A0/en unknown
- 2012-05-15 DO DO2012000139A patent/DOP2012000139A/es unknown
- 2012-05-20 EC ECSP12011930 patent/ECSP12011930A/es unknown
- 2012-05-22 TN TNP2012000248A patent/TN2012000248A1/en unknown
- 2012-05-23 CL CL2012001321A patent/CL2012001321A1/es unknown
- 2012-05-28 GT GT201200164A patent/GT201200164A/es unknown
- 2012-05-30 CR CR20120296A patent/CR20120296A/es not_active Application Discontinuation
- 2012-06-21 MA MA34993A patent/MA33840B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| CO6440531A2 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
| EA201491028A1 (ru) | Способ получения замещенных 5-фтор-1н-пиразолопиридинов | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| UY32062A (es) | Inhibidores de beta-secretasa | |
| MX2015018048A (es) | Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
| BR112013001613A2 (pt) | compostos tricíclicos e métodos para fazer e usar os mesmos. | |
| CO6300844A2 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa | |
| HK1215579A1 (zh) | 被取代的2，3-二氫苯並呋喃基化合物和其用途 | |
| AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
| IN2012DN03182A (enExample) | ||
| UY32153A (es) | Inhibidores de piridomidinona de pi13ka(alfa) y mtor | |
| TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
| EA201170753A1 (ru) | Налмефена гидрохлорид дигидрат | |
| MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
| BR112014008783A2 (pt) | compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório | |
| EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
| CR11360A (es) | Benzotiazoles como moduladores del receptor de grelina | |
| CU20130072A7 (es) | 1 h-pirazol-5-olato sódico sustituido | |
| UY31768A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre |